# **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION

**WASHINGTON, D.C. 20549** 

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 26, 2021 (April 26, 2021)

# HealthStream, Inc. (Exact name of Registrant as Specified in Its Charter)

**Tennessee** (State or Other Jurisdiction of Incorporation)

000-27701

(Commission File Number)

62-1443555 (IRS Employer Identification No.)

500 11th Avenue North, Suite 1000, Nashville, Tennessee (Address of Principal Executive Offices)

37203 (Zip Code)

Registrant's Telephone Number, Including Area Code: 615-301-3100

**Not Applicable** 

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

	Title of each Class	Trading Symbol(s)	Name of each exchange on which registered			
C	Common Stock (Par Value \$0.00)	HSTM	Nasdaq Global Select Market			
	appropriate box below if the Form 8-K filin (see General Instructions A.2. below):	g is intended to simultaneously satisfy the filing of	obligation of the registrant under any of the following			
	Written communications pursuant to Rule	425 under the Securities Act (17 CFR 230.425)				
	Soliciting material pursuant to Rule 14a-12	2 under the Exchange Act (17 CFR 240.14a-12)				
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))					
	Pre-commencement communications pursu	nant to Rule 13e-4(c) under the Exchange Act (17	CFR 240.13e-4(c))			
	r check mark whether the registrant is an em Rule 12b-2 of the Securities Exchange Act	nerging growth company as defined in Rule 405 of 1934 (§ 240.12b-2 of this chapter).	of the Securities Act of 1933 (§ 230.405 of this			
Emerging	growth company $\square$					
	1 0	rk if the registrant has elected not to use the exter ant to Section 13(a) of the Exchange Act. $\Box$	nded transition period for complying with any new or			

#### Item 2.02 Results of Operations and Financial Condition.

On April 26, 2021, HealthStream, Inc. (the "Company") issued a press release announcing results of operations for the first quarter ended March 31, 2021 and updated guidance for the full year 2021, the text of which is set forth in Exhibit 99.1.

# Item 7.01 Regulation FD Disclosure

On April 26, 2021, the Company issued a press release announcing results of operations for the first quarter ended March 31, 2021 and updated guidance for the full year 2021, the text of which is set forth in Exhibit 99.1.

#### Item 9.01 Financial Statements and Exhibits.

#### (d) Exhibits.

Exhibit Number	Description
99.1*	Press release dated April 26, 2021
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).
* Fur	nished herewith.

### **Exhibit Index**

Exhibit Number	Description
99.1*	Press release dated April 26, 2021
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).
* Fur	
* Fur	nished herewith.

# **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the unders	igned
thereunto duly authorized.	

	HealthStream, Inc	с.	
Date: April 26, 2021	Ву:	/s/ Scott A. Roberts	
		Scott A. Roberts	
		Chief Financial Officer	



Exhibit 99.1

Contact: Scott A. Roberts
Chief Financial Officer
(615) 301-3182
ir@healthstream.com

Media:
Mollie Condra, Ph.D.
Vice President,
Investor Relations &
Communications
(615) 301-3237
mollie.condra@healthstream.com

# **HEALTHSTREAM ANNOUNCES FIRST QUARTER 2021 RESULTS**

**NASHVILLE, Tenn. (April 26, 2021)**—HealthStream, Inc. (Nasdaq: HSTM), a leading provider of workforce and provider solutions for the healthcare industry, announced today results for the first guarter ended March 31, 2021.

- Revenues of \$63.5 million in the first quarter of 2021, up 3% from \$61.6 million in the first quarter of 2020.
- Operating income of \$3.3 million in the first quarter of 2021, down 54% from \$7.2 million in the first quarter of 2020, which
  comparison was negatively impacted by a one-time contractual adjustment to cost of revenues in the amount of \$3.4 million in the
  first quarter of 2020.
- Net income of \$2.3 million in the first quarter of 2021, down 68% from \$7.1 million in the first quarter of 2020, which comparison was negatively impacted by \$2.6 million from the contractual adjustment in the first quarter of 2020 referenced above.
- Earnings per share (EPS) of \$0.07 per share (diluted) in the first quarter of 2021 compared to \$0.22 in the first quarter of 2020, which was impacted by \$0.08 from the contractual adjustment in the first quarter of 2020 referenced above.
- Adjusted EBITDA1 of \$13.6 million in the first quarter of 2021, up 14% from \$11.9 million in the first quarter of 2020.
- Completed the acquisition of ComplyALIGN, a Chicago-based healthcare technology company, on January 19, 2021, for \$2.0 million in cash.
- Kevin O'Hara joined HealthStream as Senior Vice President & General Manager, Platform Solutions; Scott Fenstermacher was named Senior Vice President, Sales.

#### **Financial Results:**

#### First Quarter 2021 Compared to First Quarter 2020

Revenues for the first quarter of 2021 increased by \$1.9 million, or three percent, to \$63.5 million, compared to \$61.6 million for the first quarter of 2020. Revenues from our Workforce Solutions segment were \$51.3 million for the first quarter of 2021, compared to \$49.8 million for the first quarter of 2020. Contributions from recent acquisitions and growth in other workforce solutions more than offset the expected decline in revenues from legacy resuscitation products. While revenues from legacy resuscitation products effectively ceased at the end of 2020, revenues for the first quarter of 2021 included \$1.8 million from legacy resuscitation products as some agreements will expire in early 2021, compared to \$11.2 million in revenues from legacy resuscitation products during the first quarter of 2020. Workforce revenues also benefited from \$0.4 million of growth from professional services, primarily associated with recently acquired businesses. Revenues from our Provider Solutions segment were \$12.2 million for the first quarter of 2021, compared to \$11.7 million for the first quarter of 2020. Revenue growth of \$0.5 million was attributable to new VerityStream subscriptions.

1 Adjusted EBITDA is a non-GAAP financial measure. A reconciliation of adjusted EBITDA to net income and disclosure regarding why we believe adjusted EBITDA provides useful information to investors is included later in this release.

HealthStream Announces First Quarter 2021 Results Page 2 April 26, 2021



Generally accepted accounting principles (GAAP) require companies to write down beginning balances of acquired deferred revenue as part of "fair value" accounting. During the first quarter of 2021, HealthStream reported a reduction of \$1.6 million to revenue and operating income and a reduction of \$0.4 million to net income as a result of deferred revenue write-downs from acquisitions. During the first quarter of 2020, HealthStream reported a reduction of \$0.1 million to revenue and operating income and a reduction of \$34,000 to net income as a result of deferred revenue write-downs from acquisitions.

Operating income was \$3.3 million for the first quarter of 2021, down 54 percent from \$7.2 million for the first quarter of 2020. The decrease in operating income was primarily attributable to the \$3.4 million one-time favorable contractual adjustment to royalty expense resulting in a reduction to cost of revenues in the first quarter of 2020. Also contributing to the decrease are higher operating expenses primarily associated with acquisitions completed during 2020 and the first quarter of 2021. Partially offsetting these declines in operating income was a \$1.0 million non-recurring, non-cash benefit during the first quarter of 2021 related to the reduction of paid time off (PTO) expense resulting from modifications to the Company's PTO policy.

Net income was \$2.3 million in the first quarter of 2021, down 68 percent from \$7.1 million in the first quarter of 2020, and EPS from was \$0.07 per share (diluted) in the first quarter of 2021, compared to \$0.22 per share (diluted) for the first quarter of 2020, with each comparison negatively impacted in the amount of \$2.6 million, or \$0.08 per diluted share, from the contractual adjustment in the first quarter of 2020 referenced above.

Adjusted EBITDA was \$13.6 million for the first quarter of 2021, up 14 percent from \$11.9 million in the first quarter of 2020.

At March 31, 2021, the Company had cash and cash equivalents and marketable securities of \$56.0 million. Capital expenditures incurred during the first quarter of 2021 were \$4.3 million.

#### **Other Business Updates**

At March 31, 2021, we had approximately 4.34 million contracted subscriptions to hStream™, our Platform-as-a-Service technology. hStream technology enables healthcare organizations and their respective workforces to easily connect to and gain value from the growing HealthStream ecosystem of applications, tools, and content.

On January 19, 2021, the Company acquired ProcessDATA, Ltd. (d/b/a ComplyALIGN and HospitalPORTAL), a Chicago-based healthcare technology company, for \$2.0 million in cash, subject to customary purchase price adjustments. This acquisition adds an innovative, SaaS-based policy management system to our suite of solutions for healthcare organizations.

### **Management Team Announcements**

On January 1, 2021, Kevin O'Hara joined HealthStream as Senior Vice President & General Manager, Platform Solutions, and Scott Fenstermacher—who previously served as Vice President, Sales—was promoted to Senior Vice President, Sales. Both new members of the Company's executive team have approximately a decade of experience at HealthStream with Mr. O'Hara's initial tenure served from 2001 – 2011 and Mr. Fenstermacher's tenure beginning in early 2012. In his current position, Mr. O'Hara is responsible for the growth, development, and integration of the hStream platform throughout the Company. As Senior Vice President, Sales, Mr. Fenstermacher is responsible for the sales efforts of HealthStream's Workforce Development and Platform solutions, providing executive-level guidance and direction.



#### **Financial Outlook for 2021**

The Company is updating its guidance for 2021 for the measures set forth below, including adjusted EBITDA, a non-GAAP financial measure as defined later in this release. For a reconciliation of projected adjusted EBITDA to projected net income (loss) (the most comparable GAAP measure) for 2021, see the table included on page 10 of this release.

	 Full Year 2021 Guidance			
Revenue				
Workforce Solutions	\$ 197.0	- \$	205.0 million	
Provider Solutions	48.0	-	50.0 million	
Consolidated	\$ 245.0	- \$	255.0 million	
Adjusted EBITDA1	\$ 40.0	- \$	44.0 million	
Capital Expenditures	\$ 25.0	- \$	27.0 million	

<sup>1</sup> Adjusted EBITDA is a non-GAAP financial measure. A reconciliation of projected adjusted EBITDA to projected net loss (the most comparable GAAP measure) is included later in this release.

The Company's guidance for 2021 as set forth above reflects the Company's assumptions regarding, among other things, the COVID-19 pandemic as noted below, anticipated integration costs and additional investments in sales, marketing, and product development in 2021 for recently acquired companies, and estimated deferred revenue write-downs of \$4.0 to \$4.3 million during 2021 as the result of recent acquisitions, which would result in corresponding reductions to net revenues and operating income during 2021.

The Company's financial guidance assumes that public health conditions associated with the pandemic and general economic conditions (including conditions impacting healthcare organizations) continue to improve over the course of the year, including that COVID-19 vaccines continue to be successfully distributed and perform according to current expectations and that new variants of the virus, or other unknown variants, do not further impede recovery from the pandemic.

Commenting on first quarter 2021 results, Robert A. Frist, Jr., Chief Executive Officer of HealthStream, said, "We are starting the year strong with our team managing to outpace several anticipated headwinds to produce record adjusted EBITDA in the first quarter. Moreover, we acquired ComplyALIGN, contracted 121,000 net new hStream subscriptions to our platform, and added two outstanding executives to our management team in the quarter. Our focus remains on supporting healthcare organizations in developing their workforce and improving outcomes—and I believe our success in doing that positions us for sustained growth in 2021 as reflected in our increased guidance."

A conference call with Robert A. Frist, Jr., Chief Executive Officer, Scott A. Roberts, Chief Financial Officer and Senior Vice President, and Mollie Condra, Vice President of Investor Relations and Corporate Communications, will be held on Tuesday, April 27, 2021, at 9:00 a.m. (ET). To listen to the conference, please dial 877-647-2842 (no conference ID needed) if you are calling within the domestic U.S. or Canada. If you are an international caller, please dial 914-495-8564 (no conference ID needed). The conference may also be accessed by going to <a href="http://ir.healthstream.com/events.cfm">http://ir.healthstream.com/events.cfm</a> for the simultaneous Webcast of the call, which will subsequently be available for replay. The replay telephone numbers are 855-859-2056 (conference ID #5087987) for U.S. and Canadian callers and 404-537-3406 (conference ID #5087987) for international callers.

HealthStream Announces First Quarter 2021 Results Page 4 April 26, 2021



#### **Use of Non-GAAP Financial Measures**

This press release presents adjusted EBITDA, a non-GAAP financial measure used by management in analyzing the Company's financial results and ongoing operational performance.

In order to better assess the Company's financial results, management believes that net income excluding the impact of the deferred revenue write-downs associated with fair value accounting for acquired businesses and before interest, income taxes, stock based compensation, depreciation and amortization, changes in fair value of non-marketable equity investments, the derecognition of non-cash expense resulting from the PTO expense reduction in the first quarter of 2021 and the resolution of a mutual disagreement related to various elements of a past partnership which resulted in a reduction to cost of sales in the first quarter of 2020 ("adjusted EBITDA") is a useful measure for evaluating the operating performance of the Company because adjusted EBITDA reflects net income adjusted for certain GAAP accounting, non-cash and non-operating items which may not, in any such case, fully reflect the underlying operating performance of our business. We also believe that adjusted EBITDA is useful to investors to assess the Company's ongoing operating performance and to compare the Company's operating performance between periods. In addition, beginning in 2021, executive bonuses are based on the achievement of adjusted EBITDA targets.

The Company has revised its definition of adjusted EBITDA to adjust for the derecognition of non-cash expense during the first quarter of 2021 related to the reduction of PTO expense resulting from modifications to the Company's PTO policy. The Company has included an adjustment in the definition of adjusted EBITDA for the derecognition of this non-cash expense because this amount constitutes a non-cash benefit that management believes is outside of the ordinary course of the Company's operations and is not reflective of the Company underlying operating performance.

As noted above, the definition of adjusted EBITDA includes an adjustment for the impact of the deferred revenue write-downs associated with fair value accounting for acquired businesses. Following the completion of any acquisition by the Company, the Company must record the acquired deferred revenue at fair value as defined in GAAP, which may result in a write-down of deferred revenue. If the Company is required to record a write-down of deferred revenue, it may result in lower recognized revenue, operating income, and net income in subsequent periods. Revenue for any such acquired business is deferred and is typically recognized over a one-to-two year period following the completion of any particular acquisition, so our GAAP revenues for this one-to-two year period will not reflect the full amount of revenues that would have been reported if the acquired deferred revenue was not written down to fair value. Management believes that including an adjustment in the definition of adjusted EBITDA for the impact of the deferred write-downs associated with fair value accounting for acquired businesses provides useful information to investors because the deferred revenue write-down recognized in periods after an acquisition may, given the nature of this non-cash accounting impact, cause our GAAP financial results during such periods to not fully reflect our underlying operating performance and thus adjusting for this amount may assist in comparing the Company's results of operations between periods.

Adjusted EBITDA is a non-GAAP financial measure and should not be considered as a measure of financial performance under GAAP. Because adjusted EBITDA is not a measurement determined in accordance with GAAP, adjusted EBITDA is susceptible to varying calculations. Accordingly, adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies and have limitations as analytical tools.

This non-GAAP financial measure should not be considered a substitute for, or superior to, measures of financial performance, which are prepared in accordance with GAAP. Investors are encouraged to review the reconciliations of adjusted EBITDA to net income (loss) (the most comparable GAAP measure), which is set forth below in this release.

HealthStream Announces First Quarter 2021 Results Page 5 April 26, 2021



#### **About HealthStream**

HealthStream (Nasdaq: HSTM) is dedicated to improving patient outcomes through the development of healthcare organizations' greatest asset: their people. Our unified suite of solutions is contracted by healthcare organizations across the U.S. for workforce development, training & learning management, nurse & staff scheduling, clinical education, credentialing, privileging, provider enrollment, performance assessment, and managing simulation-based education programs. HealthStream's corporate office is in Nashville, Tennessee. For more information, visit http://www.healthstream.com or call 800-521-0574.



# HEALTHSTREAM, INC. Condensed Consolidated Statements of Income (In thousands, except per share data) (Unaudited)

		Three Months Ended				
	N	larch 31, 2021		March 31, 2020		
Revenues, net	\$	63,468	\$	61,572		
Operating costs and expenses:						
Cost of revenues (excluding depreciation and amortization)		21,237		20,359		
Product development		9,361		7,468		
Sales and marketing		8,924		9,188		
Other general and administrative expenses		11,493		9,864		
Depreciation and amortization		9,153		7,449		
Total operating costs and expenses	·	60,168		54,328		
Operating income		3,300		7,244		
Other (loss) income, net		(87)		1,706		
Income before income tax provision		3,213		8,950		
Income tax provision		922		1,858		
Net income	\$	2,291	\$	7,092		
	<del></del>			<u> </u>		
Net income per share:						
Basic	\$	0.07	\$	0.22		
Diluted	<u>*</u>	0.07	\$	0.22		
Bildica	Ψ	0.01	<u>*</u>	0.22		
Majorita de como de aconse el aconse de aconse						
Weighted average shares of common stock outstanding:		04 504		00.004		
Basic		31,504		32,334		
Diluted		31,526		32,357		



# HEALTHSTREAM, INC. Condensed Consolidated Balance Sheets (In thousands) (Unaudited)

		March 31, 2021	D	ecember 31, 2020
ASSETS		2021		2020
Current assets:				
Cash and cash equivalents	\$	45,348	\$	36,566
Marketable securities		10,622		9,928
Accounts and unbilled receivables, net		37,183		46,100
Prepaid and other current assets		21,824		22,131
Total current assets		114,977		114,725
Capitalized software development, net		27,190		26,631
Property and equipment, net		20,653		22,218
Operating lease right of use assets, net		27,276		28,081
Goodwill and intangible assets, net		279,447		279,155
Deferred tax assets		974		974
Deferred commissions		21,375		19,907
Other assets		9,790		8,622
Total assets	\$	501,682	\$	500,313
LIABILITIES AND SHAREHOLDERS' EQUITY				
Current liabilities:				
Accounts payable, accrued and other liabilities	\$	28,516	\$	38,266
Deferred revenue		88,390		81,176
Total current liabilities		116,906		119,442
Deferred tax liabilities		16,560		14,523
Deferred revenue, non-current		1,518		1,603
Operating lease liability, noncurrent		27,675		28,479
Other long-term liabilities		2,218		2,204
Total liabilities		164,877		166,251
Shareholders' equity:				
Common stock		272,001		271,784
Accumulated other comprehensive income		235		1
Retained earnings		64,569		62,277
Total shareholders' equity	_	336,805		334,062
Total liabilities and shareholders' equity	\$	501,682	\$	500,313



# HEALTHSTREAM, INC. Condensed Consolidated Statements of Cash Flows (In thousands) (Unaudited)

Page	(Gliadaltea)				
Operating activities:         Zo.291         \$ 7.092           Net income         \$ 2.291         \$ 7.092           Adjustments to reconcile net income to net cash provided by operating activities:         9,153         7,449           Share-based compensation         616         550           Amortization of deferred commissions         2,133         2,159           Deferred income taxes         486         500           Provision for doubfful accounts         142         288           Loss on equity method investments         5         111           Non-cash paid time off expense         (1,011)         —           Non-cash paid time off expense         (1,011)         —           Non-cash royalty expense         (1,011)         —           Changes in fair value of non-marketable equity investments         7         (3,440)           Changes in assets and liabilities:         3         (3,722)         (3,935)           Accounts and unbilled receivables         7,379         (4,573)           Prepaid and other assets         (5,644)         (5,333)           Deferred revenue         6,862         6,852           Net cash provided by operating activities         (705         6,595           Payments to acquire non-marketable securiries			Three Months Ended		
Operating activities:         \$ 2,291         \$ 7,092           Adjustments to reconcile net income to net cash provided by operating activities:         9,153         7,449           Depreciation and amortization         616         550           Share-based compensation         616         550           Amortization of deferred commissions         2,133         2,159           Deferred income taxes         486         500           Provision for doubiful accounts         142         288           Loss on equity method investments         54         11           Non-cash paid time off expense         (1,011)         —           Change in fair value of non-marketable equity investments         15         47           Change in fair value of non-marketable equity investments         7,379         (4,573)           Change in assets and liabilities:         7,379         (4,573)           Accounts payable, accrued and other liabilities         7,379         (4,573)           Prepaid and other assets         (3,372)         (3,935)           Accounts payable, accrued and other liabilities         (5,644)         (5,333)           Deferred revenue         6,862         6,453           Net cash provided by operating activities         (705)         6,595		M			,
Net income         \$ 2,291         \$ 7,092           Adjustments to reconcile net income to net cash provided by operating activities:         7,499           Depreciation and amortization         9,153         7,449           Share-based compensation         616         550           Amortization of deferred commissions         2,133         2,159           Deferred income taxes         486         500           Provision for doubtful accounts         142         288           Loss on equity method investments         54         11           Non-cash paid time off expense         (1,011)         —           Non-cash poulty method investments         54         11           Non-cash royally expense         —         (3,440)           Change in fair value of non-marketable equity investments         —         (1,152)           Other         57         47           Changes in assets and liabilities:         7,379         (4,573)           Accounts and unbilled receivables         7,379         (4,573)           Accounts payable, accrued and other liabilities         (5,644)         (5,333)           Deferred revenue         6,862         6,862         6,453           Net cash provided by operating activities         (705)         6,595 <th></th> <th></th> <th>2021</th> <th></th> <th>2020</th>			2021		2020
Adjustments to reconcile net income to net cash provided by operating activities:         9,153         7,449           Depreciation and amortization         9,153         7,449           Share-based compensation         616         550           Amortization of deferred commissions         2,133         2,159           Deferred income taxes         486         500           Provision for doubtful accounts         142         288           Loss on equity method investments         54         11           Non-cash paid time of rexpense         -         (3,440)           Change in fair value of non-marketable equity investments         -         (1,152)           Other         15         47           Changes in assets and liabilities:         15         47           Changes in assets and liabilities:         15         47           Prepaid and other assets         (3,372)         (3,935)           Accounts and unbilled receivables         (3,372)         (3,935)           Prepaid and other assets         (3,372)         (3,935)           Accounts payable, accrued and other liabilities         (5,644)         (5,333)           Deferred revenue         6,862         6,453           Net cash provided by operating activities         (705)		Φ.	0.001	Φ.	7.000
Depreciation and amortization         9,153         7,449           Share-based compensation         616         550           Amortization of deferred commissions         2,133         2,159           Deferred income taxes         486         500           Provision for doubtful accounts         142         288           Loss on equity method investments         54         11           Non-cash poyalty expense         (1,011)         —           Non-cash royalty expense         —         (3,440)           Change in fair value of non-marketable equity investments         —         (1,152)           Other         15         47           Changes in assets and liabilities:         —         (3,372)         (3,395)           Accounts and unbilled receivables         7,379         (4,573)         (4,573)           Accounts payable, accrued and other liabilities         (3,372)         (3,935)           Accounts payable, accrued and other liabilities         (5,644)         (5,333)           Deferred revenue         6,862         6,453           Net cash provided by operating activities         (705)         6,952           Business combinations, net of cash acquired         (731)         (21,421)           Changes in marketable equity investm		\$	2,291	\$	7,092
Share-based compensation         616         550           Amortization of deferred commissions         2,133         2,159           Deferred income taxes         486         500           Provision for doubtful accounts         142         288           Loss on equity method investments         54         11           Non-cash paid time off expense         (1,011)         —           Non-cash royalty expense         —         (1,152)           Change in fair value of non-marketable equity investments         —         (1,52)           Other         —         7,379         (4,573)           Accounts and unbilled receivables         7,379         (4,573)           Prepaid and other assets         (3,372)         (3,935)           Accounts payable, accrued and other liabilities         (5,644)         (5,333)           Deferred revenue         6,862         6,453           Net cash provided by operating activities         (705)         6,595           Net cash provided by operating activities         (705)         6,595           Payments to acquire non-marketable equity investments         (1,000)         —           Purchases of property and equipment         (5,326)         (4,068)           Net cash used in investing activities <t< td=""><td></td><td></td><td>0.450</td><td></td><td>7.440</td></t<>			0.450		7.440
Amortization of deferred commissions         2,133         2,159           Deferred income taxes         486         500           Provision for doubfful accounts         142         288           Loss on equity method investments         54         11           Non-cash royalty expense         —         (3,440)           Change in fair value of non-marketable equity investments         —         (1,152)           Other         15         47           Changes in assets and liabilities:         T         (7,379         (4,573)           Accounts and unbilled receivables         7,379         (4,573)           Accounts payable, accrued and other liabilities         (5,644)         (5,333)           Accounts payable, accrued and other liabilities         (5,644)         (5,333)           Deferred revenue         6,862         6,453           Net cash provided by operating activities         19,104         6,116           Investing activities:           Business combinations, net of cash acquired         (731)         (21,421)           Changes in marketable securities         (705)         6,595           Payments to acquire non-marketable quity investments         (1,000)         —           Purchases of property and equipment         (1,08) <td></td> <td></td> <td></td> <td></td> <td></td>					
Deferred income taxes         486         500           Provision for doubtful accounts         142         288           Loss on equity method investments         54         111           Non-cash paid time off expense         (1,011)         —           Non-cash royalty expense         —         (3,440)           Change in fair value of non-marketable equity investments         —         (1,152)           Other         15         47           Changes in assets and liabilities:         —         (4,573)           Accounts and unbilled receivables         7,379         (4,573)           Prepaid and other assets         (3,372)         (3,935)           Accounts payable, accrued and other liabilities         (5,644)         (5,333)           Deferred revenue         6,862         6,453           Net cash provided by operating activities         (731)         (21,421)           Investing activities:           Business combinations, net of cash acquired         (731)         (21,421)           Changes in marketable securities         (705)         6,595           Payments to acquire non-marketable equity investments         (1,000)         —           Purchases of property and equipment         (5,326)         (4,068)					
Provision for doubtful accounts         142         288           Loss on equity method investments         54         11           Non-cash paid time off expense         (1,011)         —           Non-cash royalty expense         —         (3,440)           Change in fair value of non-marketable equity investments         —         (1,152)           Other         15         47           Changes in assets and liabilities:         7,379         (4,573)           Accounts and unbilled receivables         7,379         (4,573)           Prepaid and other assets         (3,372)         (3,935)           Accounts payable, accrued and other liabilities         (5,644)         (5,333)           Deferred revenue         6,862         6,453           Net cash provided by operating activities         19,104         6,116           Investing activities:           Business combinations, net of cash acquired         (731)         (21,421)           Changes in marketable securities         (705)         6,595           Payments to acquire non-marketable equity investments         (1,000)         —           Purchases of property and equipment         (1,988)         (1,010)           Payments associated with capitalized software development         (5,326)					
Loss on equity method investments         54         11           Non-cash paid time off expense         (1,011)         —           Non-cash royally expense         —         (3,440)           Change in fair value of non-marketable equity investments         —         (1,152)           Other         15         47           Changes in assets and liabilities:         —         (4,573)           Accounts and unbilled receivables         7,379         (4,573)           Prepaid and other assets         (3,372)         (3,935)           Accounts payable, accrued and other liabilities         (5,644)         (5,333)           Deferred revenue         6,862         6,453           Net cash provided by operating activities         19,104         6,116           Investing activities:           Business combinations, net of cash acquired         (731)         (21,212)           Changes in marketable securities         (705)         6,595           Payments to acquire non-marketable equity investments         (1,000)         —           Purchases of property and equipment         (1,888)         (1,010)           Payments to acquire non-marketable equity investments         (3,93)         (373)           Repurchases of property and equipment         (3,93)					
Non-cash paid time off expense         (1,011)         —           Non-cash royalty expense         —         (3,440)           Change in fair value of non-marketable equity investments         15         47           Other         15         47           Changes in fair value of non-marketables         15         47           Changes in assets and liabilities:         -         (4,573)           Accounts and unbilled receivables         7,379         (4,573)           Prepaid and other assets         (3,372)         (3,935)           Accounts payable, accrued and other liabilities         (5,644)         (5,333)           Deferred revenue         6,862         6,453           Net cash provided by operating activities         19,104         6,116           Investing activities:           Business combinations, net of cash acquired         (731)         (21,421)           Changes in marketable securities         (705)         6,595           Payments to acquire non-marketable equity investments         (1,000)         —           Purchases of property and equipment         (1,898)         (1,010)           Payments to acquire non-marketable equity investments         (1,058)         (4,058)           Net cash used in investing activities         (3,372)					
Non-cash royalty expense         —         (3,440)           Change in fair value of non-marketable equity investments         —         (1,152)           Other         15         47           Changes in assets and liabilities:         —         (4,573)           Accounts and unbilled receivables         7,379         (4,573)           Prepaid and other assets         (3,372)         (3,935)           Accounts payable, accrued and other liabilities         (5,644)         (5,333)           Deferred revenue         6,862         6,453           Net cash provided by operating activities         19,104         6,116           Investing activities:         —         —           Business combinations, net of cash acquired         (731)         (21,421)           Changes in marketable securities         (705)         6,595           Payments to acquire non-marketable equity investments         (1,000)         —           Purchases of property and equipment         (1,898)         (1,010)           Payments associated with capitalized software development         (5,326)         (4,068)           Net cash used in investing activities         (399)         (373)           Repurchases of common stock         —         (9,876)           Payment of cash dividends <td></td> <td></td> <td></td> <td></td> <td>11</td>					11
Change in fair value of non-marketable equity investments         —         (1,152)           Other         15         47           Changes in assets and liabilities:         —         (4,573)           Accounts and unbilled receivables         7,379         (4,573)           Prepaid and other assets         (3,372)         (3,935)           Accounts payable, accrued and other liabilities         (5,644)         (5,333)           Deferred revenue         6,862         6,453           Net cash provided by operating activities         19,104         6,116           Investing activities:           Business combinations, net of cash acquired         (731)         (21,421)           Changes in marketable securities         (705)         6,595           Payments to acquire non-marketable equity investments         (1,000)         —           Purchases of property and equipment         (1,898)         (1,010)           Payments associated with capitalized software development         (5,326)         (4,068)           Net cash used in investing activities         (9,660)         (19,904)           Financing activities:           Taxes paid related to net settlement of equity awards         (399)         (373)           Repurchases of common stock         —			(1,011)		(2.440)
Other         15         47           Changes in assets and liabilities:         7,379         (4,573)           Accounts and unbilled receivables         7,379         (4,573)           Prepaid and other assets         (3,372)         (3,935)           Accounts payable, accrued and other liabilities         (5,644)         (5,333)           Deferred revenue         6,862         6,453           Net cash provided by operating activities         19,104         6,116           Investing activities:           Business combinations, net of cash acquired         (731)         (21,421)           Changes in marketable securities         (705)         6,595           Payments to acquire non-marketable equity investments         (1,000)         —           Purchases of property and equipment         (1,898)         (1,010)           Payments associated with capitalized software development         (5,326)         (4,068)           Net cash used in investing activities         (9,660)         (19,904)           Financing activities:           Taxes paid related to net settlement of equity awards         (399)         (373)           Repurchases of common stock         —         (9,876)           Payment of cash dividends         (12)         (30) <td></td> <td></td> <td>_</td> <td></td> <td></td>			_		
Changes in assets and liabilities:         7,379         (4,573)           Accounts and unbilled receivables         7,379         (4,573)           Prepaid and other assets         (3,372)         (3,935)           Accounts payable, accrued and other liabilities         (5,644)         (5,333)           Deferred revenue         6,862         6,453           Net cash provided by operating activities         19,104         6,116           Investing activities:           Business combinations, net of cash acquired         (731)         (21,421)           Changes in marketable securities         (705)         6,595           Payments to acquire non-marketable equity investments         (1,000)         —           Purchases of property and equipment         (1,898)         (1,010)           Payments associated with capitalized software development         (5,326)         (4,068)           Net cash used in investing activities         (9,660)         (19,904)           Financing activities:           Taxes paid related to net settlement of equity awards         (399)         (373)           Repurchases of common stock         —         (9,876)           Payment of cash dividends         (12)         (30)           Net cash used in financing activities         (41					
Accounts and unbilled receivables         7,379         (4,573)           Prepaid and other assets         (3,372)         (3,935)           Accounts payable, accrued and other liabilities         (5,644)         (5,333)           Deferred revenue         6,862         6,453           Net cash provided by operating activities         19,104         6,116           Investing activities:           Business combinations, net of cash acquired         (731)         (21,421)           Changes in marketable securities         (705)         6,595           Payments to acquire non-marketable equity investments         (1,000)         —           Purchases of property and equipment         (1,898)         (1,010)           Payments associated with capitalized software development         (5,326)         (4,068)           Net cash used in investing activities         (9,660)         (19,904)           Financing activities:           Taxes paid related to net settlement of equity awards         (399)         (373)           Repurchases of common stock         —         (9,876)           Payment of cash dividends         (12)         (30)           Net cash used in financing activities         (411)         (10,279)           Effect of exchange rate changes on cash and cash equiv			15		47
Prepaid and other assets         (3,372)         (3,935)           Accounts payable, accrued and other liabilities         (5,644)         (5,333)           Deferred revenue         6,862         6,453           Net cash provided by operating activities         19,104         6,116           Investing activities:         8         19,104         6,116           Investing activities:         8         19,104         6,116           Investing activities:         10,000         10,100			7 070		(4.572)
Accounts payable, accrued and other liabilities         (5,644)         (5,333)           Deferred revenue         6,862         6,453           Net cash provided by operating activities         19,104         6,116           Investing activities:           Business combinations, net of cash acquired         (731)         (21,421)           Changes in marketable securities         (705)         6,595           Payments to acquire non-marketable equity investments         (1,000)         —           Purchases of property and equipment         (1,898)         (1,010)           Payments associated with capitalized software development         (5,326)         (4,068)           Net cash used in investing activities         (9,660)         (19,904)           Financing activities:           Taxes paid related to net settlement of equity awards         (399)         (373)           Repurchases of common stock         —         (9,876)           Payment of cash dividends         (12)         (30)           Net cash used in financing activities         (411)         (10,279)           Effect of exchange rate changes on cash and cash equivalents         (251)         (46)           Net increase (decrease) in cash and cash equivalents         8,782         (24,113)           Cas					
Deferred revenue         6,862         6,453           Net cash provided by operating activities         19,104         6,116           Investing activities:           Business combinations, net of cash acquired         (731)         (21,421)           Changes in marketable securities         (705)         6,595           Payments to acquire non-marketable equity investments         (1,000)         —           Purchases of property and equipment         (1,898)         (1,010)           Payments associated with capitalized software development         (5,326)         (4,068)           Net cash used in investing activities         (9,660)         (19,904)           Financing activities:         —         (9,876)           Taxes paid related to net settlement of equity awards         (399)         (373)           Repurchases of common stock         —         (9,876)           Payment of cash dividends         (12)         (30)           Net cash used in financing activities         (411)         (10,279)           Effect of exchange rate changes on cash and cash equivalents         (251)         (46)           Net increase (decrease) in cash and cash equivalents         8,782         (24,113)           Cash and cash equivalents at beginning of period         36,566         131,538					
Net cash provided by operating activities19,1046,116Investing activities:3(731)(21,421)Changes in marketable securities(705)6,595Payments to acquire non-marketable equity investments(1,000)—Purchases of property and equipment(1,898)(1,010)Payments associated with capitalized software development(5,326)(4,068)Net cash used in investing activities9,660)(19,904)Financing activities:Taxes paid related to net settlement of equity awards(399)(373)Repurchases of common stock—(9,876)Payment of cash dividends(12)(30)Net cash used in financing activities(411)(10,279)Effect of exchange rate changes on cash and cash equivalents(251)(46)Net increase (decrease) in cash and cash equivalents8,782(24,113)Cash and cash equivalents at beginning of period36,566131,538					
Investing activities: Business combinations, net of cash acquired (731) (21,421) Changes in marketable securities (705) 6,595 Payments to acquire non-marketable equity investments (1,000) — Purchases of property and equipment (1,898) (1,010) Payments associated with capitalized software development (5,326) (4,068) Net cash used in investing activities (9,660) (19,904)  Financing activities: Taxes paid related to net settlement of equity awards (399) (373) Repurchases of common stock — (9,876) Payment of cash dividends (12) (30) Net cash used in financing activities (411) (10,279)  Effect of exchange rate changes on cash and cash equivalents (251) (46) Net increase (decrease) in cash and cash equivalents (24,113) Cash and cash equivalents at beginning of period (36,566) 131,538					
Business combinations, net of cash acquired       (731)       (21,421)         Changes in marketable securities       (705)       6,595         Payments to acquire non-marketable equity investments       (1,000)       —         Purchases of property and equipment       (1,898)       (1,010)         Payments associated with capitalized software development       (5,326)       (4,068)         Net cash used in investing activities       (9,660)       (19,904)         Financing activities:         Taxes paid related to net settlement of equity awards       (399)       (373)         Repurchases of common stock       —       (9,876)         Payment of cash dividends       (12)       (30)         Net cash used in financing activities       (411)       (10,279)         Effect of exchange rate changes on cash and cash equivalents       (251)       (46)         Net increase (decrease) in cash and cash equivalents       8,782       (24,113)         Cash and cash equivalents at beginning of period       36,566       131,538	Net cash provided by operating activities		19,104		6,116
Changes in marketable securities(705)6,595Payments to acquire non-marketable equity investments(1,000)—Purchases of property and equipment(1,898)(1,010)Payments associated with capitalized software development(5,326)(4,068)Net cash used in investing activities(9,660)(19,904)Financing activities:Taxes paid related to net settlement of equity awards(399)(373)Repurchases of common stock—(9,876)Payment of cash dividends(12)(30)Net cash used in financing activities(411)(10,279)Effect of exchange rate changes on cash and cash equivalents(251)(46)Net increase (decrease) in cash and cash equivalents8,782(24,113)Cash and cash equivalents at beginning of period36,566131,538					
Payments to acquire non-marketable equity investments (1,000) — Purchases of property and equipment (1,898) (1,010) Payments associated with capitalized software development (5,326) (4,068) Net cash used in investing activities (9,660) (19,904)  Financing activities:  Taxes paid related to net settlement of equity awards (399) (373) Repurchases of common stock — (9,876) Payment of cash dividends (12) (30) Net cash used in financing activities (411) (10,279)  Effect of exchange rate changes on cash and cash equivalents (251) (46) Net increase (decrease) in cash and cash equivalents (24,113) Cash and cash equivalents at beginning of period 36,566 131,538	Business combinations, net of cash acquired				
Purchases of property and equipment(1,898)(1,010)Payments associated with capitalized software development(5,326)(4,068)Net cash used in investing activities(9,660)(19,904)Financing activities:Taxes paid related to net settlement of equity awards(399)(373)Repurchases of common stock—(9,876)Payment of cash dividends(12)(30)Net cash used in financing activities(411)(10,279)Effect of exchange rate changes on cash and cash equivalents(251)(46)Net increase (decrease) in cash and cash equivalents8,782(24,113)Cash and cash equivalents at beginning of period36,566131,538					6,595
Payments associated with capitalized software development Net cash used in investing activities  Financing activities:  Taxes paid related to net settlement of equity awards Repurchases of common stock Payment of cash dividends Net cash used in financing activities  Effect of exchange rate changes on cash and cash equivalents Net increase (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of period  (4,068) (4,068) (9,660) (19,904)  (399) (373) (399) (373) (399) (12) (30) (411) (10,279)  (46) (47) (47) (46) (47) (46) (47) (47) (48) (48) (48) (48) (49) (49) (49) (40) (40) (40) (40) (40) (40) (40) (40					
Net cash used in investing activities (9,660) (19,904)  Financing activities:  Taxes paid related to net settlement of equity awards (399) (373)  Repurchases of common stock — (9,876)  Payment of cash dividends (12) (30)  Net cash used in financing activities (411) (10,279)  Effect of exchange rate changes on cash and cash equivalents (251) (46)  Net increase (decrease) in cash and cash equivalents (24,113)  Cash and cash equivalents at beginning of period (36,566) 131,538					
Financing activities:  Taxes paid related to net settlement of equity awards  Repurchases of common stock  Payment of cash dividends  Net cash used in financing activities  Effect of exchange rate changes on cash and cash equivalents  Net increase (decrease) in cash and cash equivalents  Cash and cash equivalents at beginning of period  (399)  (373)  (399)  (373)  (40)  (12)  (30)  (411)  (10,279)  (46)  (45)  (46)  (47)  (46)  (47)  (46)  (47)  (46)  (47)  (47)  (47)  (48)  (48)	Payments associated with capitalized software development				
Taxes paid related to net settlement of equity awards(399)(373)Repurchases of common stock—(9,876)Payment of cash dividends(12)(30)Net cash used in financing activities(411)(10,279)Effect of exchange rate changes on cash and cash equivalents(251)(46)Net increase (decrease) in cash and cash equivalents8,782(24,113)Cash and cash equivalents at beginning of period36,566131,538	Net cash used in investing activities		(9,660)		(19,904)
Taxes paid related to net settlement of equity awards(399)(373)Repurchases of common stock—(9,876)Payment of cash dividends(12)(30)Net cash used in financing activities(411)(10,279)Effect of exchange rate changes on cash and cash equivalents(251)(46)Net increase (decrease) in cash and cash equivalents8,782(24,113)Cash and cash equivalents at beginning of period36,566131,538	Financing activities:				
Repurchases of common stock—(9,876)Payment of cash dividends(12)(30)Net cash used in financing activities(411)(10,279)Effect of exchange rate changes on cash and cash equivalents(251)(46)Net increase (decrease) in cash and cash equivalents8,782(24,113)Cash and cash equivalents at beginning of period36,566131,538			(399)		(373)
Payment of cash dividends (12) (30) Net cash used in financing activities (411) (10,279)  Effect of exchange rate changes on cash and cash equivalents (251) (46) Net increase (decrease) in cash and cash equivalents (24,113) Cash and cash equivalents at beginning of period 36,566 131,538			_		
Net cash used in financing activities(411)(10,279)Effect of exchange rate changes on cash and cash equivalents(251)(46)Net increase (decrease) in cash and cash equivalents8,782(24,113)Cash and cash equivalents at beginning of period36,566131,538			(12)		
Effect of exchange rate changes on cash and cash equivalents  Net increase (decrease) in cash and cash equivalents  Cash and cash equivalents at beginning of period  (251) (46)  8,782 (24,113)  131,538					
Net increase (decrease) in cash and cash equivalents8,782(24,113)Cash and cash equivalents at beginning of period36,566131,538	and the second sec		, ,		(==,=,=)
Cash and cash equivalents at beginning of period 36,566 131,538					
	Net increase (decrease) in cash and cash equivalents		8,782		(24,113)
Cash and cash equivalents at end of period \$ 45,348 \$ 107,425	Cash and cash equivalents at beginning of period		36,566		131,538
	Cash and cash equivalents at end of period	\$	45,348	\$	107,425



### Reconciliation of GAAP to Non-GAAP Financial Measures(1) (In thousands) (Unaudited)

	I free Months Ended March 31,			ea
		2021		2020
GAAP net income	\$	2,291	\$	7,092
Deferred revenue write-down		1,622		144
Interest income		(18)		(594)
Interest expense		32		25
Income tax provision		922		1,858
Stock based compensation expense		616		550
Depreciation and amortization		9,153		7,449
Non-cash paid time off expense		(1,011)		_
Change in fair value of non-marketable equity investments		_		(1,152)
Non-cash royalty expense		_		(3,440)
Adjusted EBITDA	\$	13,607	\$	11,932

<sup>(1)</sup> This press release contains certain non-GAAP financial measures, including adjusted EBITDA, which is used by management in analyzing its financial results and ongoing operational performance.



## Reconciliation of GAAP to Non-GAAP Financial Measures Financial Outlook for 2021 (In thousands) (Unaudited)

	Low	High
Net income (loss)	\$ (1,900)	\$ 600
Deferred revenue write-down	4,300	4,000
Interest income	(100)	(100)
Interest expense	100	100
Income tax provision (benefit)	(500)	300
Stock based compensation expense	2,500	2,800
Depreciation and amortization	36,600	37,300
Non-cash paid time off expense	(1,000)	(1,000)
Adjusted EBITDA	\$ 40,000	\$ 44,000

HealthStream Announces First Quarter 2021 Results Page 11 April 26, 2021



This press release includes certain forward-looking statements (statements other than solely with respect to historical fact), including statements regarding expectations for financial performance for 2021 as well as the anticipated impact of the COVID-19 pandemic on our financial results, that involve risks and uncertainties regarding HealthStream. These statements are based upon management's beliefs, as well as assumptions made by and data currently available to management. This information has been, or in the future may be, included in reliance on the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions that forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements to be materially different from future results, performance, or achievements expressed or implied by the forward-looking statements, including, without limitation, as the result of developments related to the COVID-19 pandemic, including, without limitation, related to the length and severity of the pandemic; the timing and availability of medical treatments and vaccines with respect to COVID-19; the timing and effectiveness of the ongoing rollout of currently available vaccines; the spread of potentially more contagious and/or virulent forms of the virus; business and economic conditions resulting from the pandemic; the impact on the pandemic on healthcare organizations; measures we are taking to respond to the pandemic; and the impact of governmental action and regulation in connection with the pandemic (including the CARES Act); as well as risks referenced in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, filed on February 25, 2021, and in the Company's other filings with the Securities and Exchange Commission from time to time. Consequently, such forward-looking information should not be regarded as a representation or warranty or statement by the Company that such projections will be realized. Many of the factors that will determine the Company's future results are beyond the ability of the Company to control or predict. Readers should not place undue reliance on forward-looking statements, which reflect management's views only as of the date hereof. The Company undertakes no obligation to update or revise any such forward-looking statements.

# # # #